A comment on 'Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: Prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders'
| Autor: | Aarne Kivioja, Tom Wiklund, Teddy Holmström, Helena Willén, A. E. Stenwig, Thor Alvegård, Christoph R. Müller, Sigbjørn Smeland, Kjell Jonsson, Odd R. Monge, Otte Brosjö, G. Follerås, Gunnar Sæter, Olle Björk, Thomas Wiebe |
|---|---|
| Přispěvatelé: | Bacci G., Longhi A., Forni C., Setola E., Ferrari E.S., Smeland S., Muller C., Saeter G. |
| Jazyk: | angličtina |
| Rok vydání: | 2003 |
| Předmět: |
Oncology
Cancer Research medicine.medical_specialty medicine.drug_class medicine.medical_treatment Salvage therapy Antimetabolite 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Etoposide 030304 developmental biology osteosarcoma neoadjiuvant chemotherapy histological response prognosis 0303 health sciences Chemotherapy Ifosfamide business.industry medicine.disease 3. Good health Discontinuation Surgery 030220 oncology & carcinogenesis Osteosarcoma Sarcoma business medicine.drug |
| Popis: | From 1990 to 1997, 113 eligible patients with classical osteosarcoma received neo-adjuvant chemotherapy consisting of high-dose methotrexate, cisplatin and doxorubicin. Good histological responders continued to receive the same therapy postoperatively, while poor responders received salvage therapy with an etoposide/ifosfamide combination. With a median follow-up of 83 months, the projected metastasis-free and overall survival rates at 5 years are 63 and 74%, respectively. Independent favourable prognostic factors for outcome were tumour volume 4.5 microM and female gender. The etoposide/ifosfamide replacement combination did not improve outcome in the poor histological responders. In conclusion, this intensive multi-agent chemotherapy results in > 70% of patients with classical osteosarcoma surviving for 5 years. The data obtained from this non-randomised study do not support discontinuation and exchange of all drugs used preoperatively in histological poor responders. As observed in previous Scandinavian osteosarcoma studies, female gender appears to be a strong predictor of a favourable outcome. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|